EAGLE PHARMS INC - EGRX STOCK NEWS

Eagle Pharmaceuticals (EGRX) reported Q1 2022 financial results with substantial growth, achieving total revenue of $115.9 million, significantly up from $41.2 million in Q1 2021. The company posted a net income of $44.1 million, or $3.47 per basic share. Key drivers included sales of $34.3 million from vasopressin and $37.2 million from PEMFEXY™. Eagle is set to acquire Acacia Pharma Group, enhancing its product offerings. With cash and receivables totaling $176.4 million, the company is positioned for further growth and diversification.

Eagle Pharmaceuticals (EGRX) is set to announce its first quarter financial results for 2022 on May 9, 2022, before the market opens. The conference call, hosted by CEO Scott Tarriff and CFO Brian Cahill, will take place at 8:30 a.m. ET. Investors can access the call via a toll-free number or through a webcast available on the company's investor relations page. The call will also be archived for 30 days. Eagle Pharmaceuticals focuses on developing innovative medicines, boasting a diverse pipeline of products aimed at enhancing patient care.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced a settlement with Hospira regarding patents linked to BENDEKA. Hospira can market its product starting January 17, 2028, or sooner under specific conditions. The settlement follows previous litigation instances where Eagle's patents were upheld. Furthermore, Eagle has been granted U.S. Patent No. 11,103,483 for bendamustine formulations, expiring in January 2031. The agreement is pending review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Eagle Pharmaceuticals has proposed an acquisition of Acacia Pharma valued at approximately €94.7 million, equivalent to €0.90 per share, payable in cash and Eagle stock. The strategic buy aims to integrate two FDA-approved products, BARHEMSYS® and BYFAVO®, targeting a combined addressable market of $3.1 billion annually. Eagle anticipates substantial financial synergies, leveraging its specialized hospital-based salesforce for accelerated product uptake. The transaction is expected to close in late Q2 2022, pending shareholder and court approval, and is projected to be earnings-accretive in 2024.

Eagle Pharmaceuticals, Inc. (EGRX) reported a Q4 2021 net loss of $(0.48) per share, with FY 2021 loss at $(0.66) per share. Adjusted non-GAAP net income for Q4 was $0.87 per share, while FY 2021 adjusted income was $2.64 per share. Early Q1 2022 revenue is projected at $120-$130 million, with adjusted EPS of $3.80-$4.10. The company initiated shipments of vasopressin, a generic alternative to Vasostrict®, and launched PEMFEXY™, a novel treatment for lung cancer. A new drug application for Landiolol is expected in Q2 2022.

Eagle Pharmaceuticals, Inc. (EGRX) will release its 2021 fourth quarter and full year financial results on March 7, 2022, before market open. A conference call hosted by CEO Scott Tarriff and CFO Brian Cahill will occur at 8:30 a.m. ET. Investors can access a replay of the call for one week post-event, along with an archived webcast available for 30 days on Eagle's website. Eagle Pharmaceuticals is dedicated to developing innovative medicines, operating within research, development, and commercialization across multiple therapeutic areas.

Eagle Pharmaceuticals has launched PEMFEXY (pemetrexed for injection), a new treatment for nonsquamous non-small cell lung cancer and mesothelioma. Sales started today, following FDA approval and a settlement with Eli Lilly. The U.S. market for ALIMTA, a competitor, reached $1.2 billion in the past year. The company anticipates substantial revenue growth from PEMFEXY in 2022. With a unique J-code, PEMFEXY is positioned to benefit both patients and providers in the oncology market.

Eagle Pharmaceuticals (EGRX) announced that AOP Health is progressing with a New Drug Application (NDA) for Landiolol, targeting a short-term reduction in ventricular rate for supraventricular tachycardia. This follows a licensing agreement from August 2021. Landiolol, already available in Japan and Europe, is expected to fill a critical need in emergency care. It has strong patent protection and anticipated market exclusivity upon approval. The FDA's collaboration suggests positive momentum, aiming for NDA submission next quarter.

Eagle Pharmaceuticals (EGRX) announced the launch of vasopressin, a generic alternative to Vasostrict, starting today, backed by 180 days of marketing exclusivity. This product, indicated for adults with vasodilatory shock, holds significant market potential as U.S. sales of Vasostrict reached $890 million as of September 30, 2021. The FDA approved the abbreviated new drug application on December 15, 2021. With an experienced sales force and existing contracts, Eagle expects substantial revenue growth from this launch in 2022.